CardioFocus raises $30.6M

Marlborough, MA-based CardioFocus has landed $30.6 million in private financing to support development of its CardioFocus Endoscopic Ablation System. Atrial fibrillation causes irregular heartbeats that can eventually lead to stroke. As Xconomy notes, the company's minimally-invasive system basically burns away the tissue that's causing atrial fibrillation.

CardioFocus' investors include first-timers Fletcher Spaght Ventures, Manatuck Hill Partners and First Alliance & Capital Invest, as well as a laundry list of previous investors. The financing will be used to launch the ablation system in Europe, where it is already approved, and start a pivotal trial in the U.S in the first half of this year. CardioFocus continues work to improve the accuracy and effectiveness of its ablation system, notes Xconomy.

- check out the release
- read the Xconomy report

ALSO: Retina Implant, which manufactures subretinal implants, has raised $18 million in venture capital funds. The German company will use the cash to continue its second clinical trial. Retina Implant release

ALSO: Palo Alto, CA-based AirXpanders has another $8 million from two VC rounds, with $5 million led by GBS Ventures and another $3 million from Oxford Finance. AirXpanders plans to start a Investigational Device Exemption (IDE) trial with mastectomy patients for its tissue expansion technology that could be used in reconstructive surgery. AirXpanders release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.